PRESS RELEASE
The Biomedical Research Hub Will Occupy 25,698 Square Feet of Space at 1375 West Fulton
CZ Biohub Chicago Will Forge New Links Between World-Class Academic Research at its Partner Universities and the Burgeoning Chicago Biotech Community
CHICAGO – March 24, 2023 – Trammell Crow Company (TCC), a global commercial real estate developer, signed a lease with Chan Zuckerberg Biohub Chicago (CZ Biohub Chicago), a new biomedical research institute that brings together scientists from Northwestern University, the University of Chicago, and the University of Illinois Urbana-Champaign. CZ Biohub Chicago will occupy 25,698 square feet of space at 1375 West Fulton, which is part of TCC’s two-building, 725,000-square-foot Fulton Labs Campus in Chicago’s Fulton Market neighborhood.
“We are excited to welcome Chan Zuckerberg Biohub Chicago to our Fulton Labs Campus this spring. Their organization is on the cutting edge of biotech discovery and development. We are humbled that they chose the flourishing advanced sciences ecosystem at Fulton Labs as their new home,” said Johnny Carlson, Principal with TCC’s Midwest office. “Our goal when we first sought to build Fulton Labs was to create a state-of-the-art environment for the incredible talent Chicago has always produced to be able to bring their ideas and patient-saving products to life here at home. We are energized by the progress our city has made as a leading life science cluster and we are looking forward to delivering more world-class facilities to support the continued growth.”
Announced earlier this month, CZ Biohub Chicago is part of the Chan Zuckerberg Biohub Network, a groundbreaking collaborative model for scientific research that brings together leading research institutions in different geographical regions. CZ Biohub Chicago researchers will engineer technologies to make precise, molecular-level measurements of biological processes within human tissues, with an ultimate goal of understanding and treating the inflammatory states that underlie many diseases.
“We’re excited for CZ Biohub Chicago to move into its own dedicated space with state-of-the-art labs, in an area of the city that is considered a hub for innovation in the life sciences,” said Shana O. Kelley, CZ Biohub Chicago President and the Neena B. Schwartz Professor of Chemistry and Biomedical Engineering at Northwestern University. “Taking on the highly ambitious scientific grand challenge of building tools to study inflammation requires new models of collaboration and a dedicated space to create these technologies, and we’re excited to get started.”
TCC was represented in the lease transaction by Dan Lyne of CBRE.
“Fulton Market continues to be a city and state leader in business and technological development, and I’m thrilled that the Chan Zuckerberg Biohub Chicago will be another addition to a neighborhood rich in innovation,” said Illinois Governor JB Pritzker. “Biomedical research will be taken to a new level at this facility with the help of the brightest minds from local universities, and I look forward to seeing their new discoveries help people around the world.”
John Flavin, CEO of Portal Innovations, which occupies lab space and operates an early-stage life sciences fund at Fulton Labs, shared that “World-class scientists leveraging new tools such as biosensors will be pushing the frontiers to address difficult-to-treat diseases such as cancer, and autoimmune and neurological diseases that involve inflammation and its relationship to the immune system. Due in part to CZ Biohub Chicago, Chicago and the surrounding region will benefit from breakthrough therapies for patients in the future, as well venture investments, jobs in the near term, and new startup companies that will call Chicago home.”
The Fulton Labs Campus is located at 1375 West Fulton, which includes 300,000 square feet and features a Science-Ready Lab Suites program, and 400 North Aberdeen, which spans 425,000 square feet and opened in Q1 2022. Other tenants at the campus include Dimension Inx, Celadyne Technologies, Portal Innovations, Charles River Laboratories, Xeris Pharmaceuticals, Vanqua Bio and Talis Biomedical.
About Trammell Crow Company
Trammell Crow Company (TCC) is a global commercial real estate developer and wholly-owned subsidiary of CBRE Group, Inc. (NYSE:CBRE), a Fortune 500 and S&P 500 company headquartered in Dallas. Founded in 1948, TCC has developed or acquired nearly 2,900 buildings valued at $75 billion and over 655 million square feet. As of December 31, 2022, TCC had $16.9 billion of projects in process and $12.9 billion in its pipeline. It employs 700 professionals in 27 major cities throughout the United States and Europe. The company serves users of and investors in office, industrial/logistics, healthcare, life sciences and mixed-use projects, as well as multi-family residential through its operating subsidiary High Street Residential. For more information visit www.TrammellCrow.com.
Contact:
Elise Maguire Ferrara
emaguire@trammellcrow.com
The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE
